PMID: 11926380Apr 3, 2002Paper

Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects

European Journal of Nuclear Medicine and Molecular Imaging
Masahiro FujitaRobert B Innis

Abstract

The biodistribution of radioactivity after the administration of a new tracer for alpha4beta2 nicotinic acetylcholine receptors (nAChRs), [123I]5-iodo-3-[2(S)-2-azetidinylmethoxy]pyridine (5-I-A-85380), was studied in ten healthy human subjects. Following administration of 98+/-6 MBq [123I]5-I-A-85380, serial whole-body images were acquired over 24 h and corrected for attenuation. One to four brain single-photon emission tomography (SPET) images were also acquired between 2.5 and 24 h. Estimates of radiation absorbed dose were calculated using MIRDOSE 3.1 with a dynamic bladder model and a dynamic gastrointestinal tract model. The estimates of the highest absorbed dose (microGy/MBq) were for the urinary bladder wall (71 and 140), lower large intestine wall (70 and 72), and upper large intestine wall (63 and 64), with 2.4-h and 4.8-h urine voiding intervals, respectively. The whole brain activity at the time of the initial whole-body imaging at 14 min was 5.0% of the injected dose. Consistent with the known distribution of alpha4beta2 nAChRs, SPET images showed the highest activity in the thalamus. These results suggest that [123I]5-I-A-85380 is a promising SPET agent to image alpha4beta2 nAChRs in humans, with acceptable dosime...Continue Reading

Citations

Jun 3, 2009·Archives of General Psychiatry·Kelly P CosgroveJulie K Staley
Apr 15, 2004·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·D J HendersonM Kassiou
Mar 17, 2004·Current Opinion in Pharmacology·Paul A NewhouseAbhay Singh
May 21, 2003·Seminars in Nuclear Medicine·Nora D VolkowGene-Jack Wang
Dec 1, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·J T O'BrienE D Williams
Sep 17, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Alexey G MukhinElliot A Stein
Jul 28, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Irina EsterlisJulie K Staley
Nov 20, 2012·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Irina EsterlisKelly P Cosgrove
May 1, 2008·The British Journal of Radiology·S L Pimlott, K P Ebmeier
Nov 28, 2008·Neurobiology of Aging·Emma TerrièreKlaus P Ebmeier
Feb 5, 2008·Neurobiology of Aging·Effie M MitsisChristopher H van Dyck
Apr 7, 2007·Annals of the New York Academy of Sciences·Effie M MitsisChristopher H Van Dyck
Jul 9, 2011·Biochemical Pharmacology·Sharon R Letchworth, Paul Whiteaker
May 25, 2006·Nuclear Medicine and Biology·Ronald M BaldwinGilles Tamagnan
Oct 29, 2005·Nuclear Medicine and Biology·Sebastian L ObrzutEdythe D London
Mar 12, 2013·Neuropharmacology·Agnes J JasinskaElliot A Stein
Oct 1, 2011·Nuclear Medicine and Biology·Adriana Alexandre S TavaresSally L Pimlott
Feb 22, 2005·Nuclear Medicine Communications·Sally L Pimlott
Feb 22, 2005·Nuclear Medicine Communications·Sanjeet Pakrasi, John T O'Brien
Oct 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jennifer M KulakMaryka Quik
May 22, 2003·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Alane S KimesAlexey G Mukhin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.